Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival.
Hiten D PatelSunil H PatelEnrique Blanco-MartinezJake KuzbelVictor S ChenAleksander DruckElizabeth L KoehneParth M PatelChirag P DoshiNoah M HahnJean H Hoffman-CensitsStephanie BergTrinity J BivalacquaMax KatesMarcus L QuekPublished in: The Journal of urology (2021)
Patients completing 3 cycles of cisplatin-based NAC have similar pathologic response and short-term survival compared to 4 cycles. Further evaluation of patients experiencing toxicity as a potential marker of tumor chemosensitivity is needed.